Ege Üniversitesi Hastanesi malign plevral mezotelyoma hastalarının epidemiyolojik ve genel sağ kalım özellikleri
Küçük Resim Yok
Tarih
2019
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Malign plevral mazotelyoma (MPM) kötü prognozlu ölümcül bir hastalıktır. MPM için ortalama sağ kalım 4-18 ay arasında değişmektedir. MPM’de tüm tedavilere rağmen yüksek mortalite görüldüğünden, elimizdeki bilinen tüm tedaviler hastalara uygulanabilmektedir. Bu nedenle tümör evresine, hasta performansına, histolojik alt tipine göre; cerrahi, kemoterapi, radyoterapiyi içeren multimodal tedavi rejimleri söz konusu olmaktadır. Gereç ve Yöntem: Bu çalışmada Ege Üniversitesi Hastanesi veri tabanındaki 1992-2017 yılları arası 241 malign plevral mezotelyoma hastasının epidemiyolojik ve genel sağ kalım özellikleri istatistiksel açıdan global sonuçlarla karşılaştırılacak ve malign plevral mezotelyoma verileri değerlendirilecektir. Bulgular: Kayıtlı toplam 240 hastanın 154’ü (%64) erkek, 86’sı (%36) kadındı. Yas ortalaması 56 (19- 78) idi. Sağ kalım değerlendirilmesinde yapılan tedavilerin sağ kalıma etkisine bakıldığında en iyi sonucun (ortalama sağ kalım 24 ay, beş yıllık yaşam %16, p?0.001) kombine tedavi ile sağlandığı görülmüştür. Patolojik alt grupların sağ kalıma etkisine bakıldığında (Grafik 5) epiteloid mezotelyoma alt tipinin de anlamlı olarak daha iyi yaşam süresi gösterdiği bulunmuştur (ortalama sağ kalım 24 ay, beş yıllık yaşam %15, p<0,001). Sonuç: Malign mezotelyomada en başarılı sonuçlar kombine tedavilerle elde edilmektedir. Kemoterapi, radyoterapi ve cerrahi tedavinin beraber uygulanabildiği hastalarda sağ kalım uzamaktadır. Hasta sayısı arttıkça ve düzenli bir kayıt sistemi ile ilerleyen yıllarda daha sağlıklı sonuçlar verebileceğimizi düşünüyoruz.
Aim: Malignant pleural mesothelioma is a fatal disease with poor prognosis. Mean survival in mesothelioma varies between 4-18 months. Because of the high mortality rate despite all the treatments, all the known treatments can be applied to the patients. Therefore, according to tumor stage, patient performance, histological subtype; multimodal treatment regimens including surgery, chemotherapy and radiotherapy. Materials and Methods: In this study, epidemiological and general survival characteristics of 241 malignant pleural mesothelioma patients in the database of Ege University Hospital between 1992 and 2017 will be compared statistically with global results and malignant pleural mesothelioma data will be evaluated. Results: Of the total 240 patients enrolled, 154 (64%) were male and 86 (36%) were female. When the survival effect of the treatments was evaluated, it was seen that the best result (median survival 24 months, 5-year survival 16%, p < 0.001) was achieved with combined therapy. When the effect of pathological subtypes on survival was examined, it was found that epitheloid mesothelioma subtype showed significantly better survival. Conclusion: The most successful results in malignant mesothelioma are obtained with combined therapies. Survival is prolonged in patients with chemotherapy, radiotherapy and surgical treatment. We believe that as the number of patients increases and with a regular registration system, we can achieve healthier results in the years to come.
Aim: Malignant pleural mesothelioma is a fatal disease with poor prognosis. Mean survival in mesothelioma varies between 4-18 months. Because of the high mortality rate despite all the treatments, all the known treatments can be applied to the patients. Therefore, according to tumor stage, patient performance, histological subtype; multimodal treatment regimens including surgery, chemotherapy and radiotherapy. Materials and Methods: In this study, epidemiological and general survival characteristics of 241 malignant pleural mesothelioma patients in the database of Ege University Hospital between 1992 and 2017 will be compared statistically with global results and malignant pleural mesothelioma data will be evaluated. Results: Of the total 240 patients enrolled, 154 (64%) were male and 86 (36%) were female. When the survival effect of the treatments was evaluated, it was seen that the best result (median survival 24 months, 5-year survival 16%, p < 0.001) was achieved with combined therapy. When the effect of pathological subtypes on survival was examined, it was found that epitheloid mesothelioma subtype showed significantly better survival. Conclusion: The most successful results in malignant mesothelioma are obtained with combined therapies. Survival is prolonged in patients with chemotherapy, radiotherapy and surgical treatment. We believe that as the number of patients increases and with a regular registration system, we can achieve healthier results in the years to come.
Açıklama
Anahtar Kelimeler
[No Keywords]
Kaynak
Ege Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
58
Sayı
Supplement
